Skip to main content
Clinical Trials/RPCEC00000138
RPCEC00000138
Not yet recruiting
Phase 3

Comparative study of medium-term effects of D-004 and Saw palmetto (320 mg / d) in patients with benign prostatic hyperplasia (BPH)

atural Products Center (CPN)0 sites100 target enrollmentJanuary 4, 2013

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Benign Prostatic Hyperplasia
Sponsor
atural Products Center (CPN)
Enrollment
100
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 4, 2013
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
atural Products Center (CPN)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with 50 years old or older 2\. Informed consent 3\. IPSS score between 7 and 19 4\. Enlarged prostate checked by rectal examination

Exclusion Criteria

  • 1\. Prostate Cancer 2\. Prior urological surgery 3\. Urinary retention 4\. Urinary tract infection 5\. Criteria to be catheterized in next 3 months 6\. PSA\> 5 ng / mL 7\. Acute myocardial infarction, stroke, transient ischemic attack or major surgery within 6 months previous 8\. History of heart failure 9\. History of hepatic failure 10\. Blood Pressure \> 180/110 mm Hg 11\. Diagnosed neoplasias 12\. Treatment with alpha 1 adrenergic antagonists, inhibitors of 5\-alpha reductase, androgens,antiandrogens, cholinergics, anticholinergics,steroids and/or phytotherapy for BPH in 6 months prior study 13\. Alcoholism 14\. Other problems that limit its response to IPSS 15\. Common history of drug allergy or any other condition that affects patient´s health and life during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials